Patent ID: 7461006
Filing Date: 2008-12-02
Classification: G06Q,G16B,G16H,Y10S

Abstract:
1. A method for assessing and analyzing one or more drugs, adverse effects and associated risks, and patient information resulting from the use of at least one drug of interest, comprising: collecting data from a plurality of sources comprising drug information, adverse effects relating to drugs and patient information; placing collected data into a data structure, wherein data from sources not already in a relational database structure are parsed into a relational database structure; generating a relational database for relating drug information, adverse effects and patient information; assembling said patient information, drug information and adverse effects into individual cases, wherein each said case contains patient information, information related to a drug administered to that patient and a description of an adverse drug reaction; identifying a patient genotype and at least one drug proposed to be administered to a patient having said genotype; using said relational database to conduct statistical analysis across a set of cases to determine whether there is an indication of association among a drug, a reaction or group of reactions and a genotype and the distribution of that association in a population; creating a profile comprising the results of said statistical analysis that describes the behavior of the drug of interest based on patient genotype from multiple cases related to the safety of the at least one drug, wherein one or more filters is employed to select among available variables to permit recalculation of the statistical analysis; submitting the results of the statistical analysis to at least one data mining engine to compare said results against selected criteria to extract data of interest; and displaying the output from the data mining engine through an output device; wherein the analysis of the data collected involves parsing a population segment data into a plurality of population segments, the population segments having differing rates of metabolism; wherein the analysis of the data collected involves parsing a drug safety data based on a genetic perspective; wherein the drug of interest is analyzed using two or more metabolic pathways; wherein a first metabolic pathway includes the parsed population segment data relating to population segments having differing rates of metabolism; wherein a second metabolic pathway includes the parsed drug safety data relating to drug safety data based on a genomic perspective; wherein the first and the second metabolic pathways are assimilated; and wherein the first and the second metabolic pathways are correlated.